Healthcare Analyst Chen holds a conference call with Chairman & CEO Lin and CSO Mata to discuss the Company’s clinical-stage novel oral therapy for treatment of Stargardt disease and atrophic age-related macular degeneration on April 3 at 11 am hosted by H.C. Wainwright. Webcast Link
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on BLTE:
- Belite Bio to participate in a conference call with HC Wainwright
- Belite Bio Reports Full-Year 2022 Operational Highlights and Financial Results
- Belite Bio to Host Webcast on April 3, 2023 to Discuss 2022 Full Year Financial Results
- Belite Bio management to meet virtually with BTIG
- H.C. Wainwright says Belite Bio opportunity intact despite GA treatment approval
